Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 35 |
| Active Pipeline (Recruiting Now) | 19 (11) |
| Completed vs Stopped Early | 4 / 1 (2.9%) |
| Median Closed Actual Enrollment | 28 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Qilu Hospital of Shandong University | Jinan, Shandong | 18 |
| Yantai Yuhuangding Hospital | Yantai, Shandong | 4 |
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06730373 | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) | Phase II | RECRUITING |
| NCT06932068 | Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Qilu Hospital of Shandong University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.